SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

Wendy's is experiencing a surge in trading volume and social media interest as retail investors rally behind a 'Save Wendy's' campaign, targeting the stock's significant short interest for a potential squeeze. Community members are actively sharing takeover rumors, comparing the setup to previous meme stock rallies, and debating the company's long-term value alongside its dividend yield.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir Technologies is experiencing significant volatility as community sentiment splits between retail investors seeking to buy the dip following technical breakdowns and traders closely monitoring institutional sell-side pressure. While recent strategic partnerships and government contract wins serve as fundamental catalysts, the conversation is currently dominated by aggressive discussions around potential support levels and the stock's sensitivity to broader tech sector rotations.

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

The iShares Silver Trust is experiencing significant volatility as market participants debate whether recent price declines represent a fundamental shift or a temporary correction linked to broader economic uncertainty. Community discussions are heavily divided between long-term investors citing industrial shortages and physical accumulation as a floor, and traders expressing frustration over the asset's inability to sustain gains despite geopolitical headlines.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras Systems is experiencing high volatility as investors scrutinize its valuation and margin outlook following its first post-IPO earnings report. While the company announced a significant multi-year deal with OpenAI, community sentiment remains divided over concerns regarding share lockup expirations and the sustainability of its growth trajectory compared to established competitors.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

GLD is facing intense selling pressure as investors rotate out of gold, driven by concerns that persistent inflation and a strong dollar will force the Federal Reserve to maintain higher interest rates. The community is sharply divided, with bulls viewing the drop as a structural buying opportunity near key support levels, while bears are aggressively shorting the ETF, anticipating further downside as gold's safe-haven appeal wanes.

FuelCell Energy, Inc. engages in the business of developing, designing, producing, constructing, and servicing high temperature fuel cells for clean electric power generation. It operates through the following geographical segments: the United States, South Korea, and Europe. The company was founded by Bernard Baker and Martin G. Klein in 1969 and is headquartered in Danbury, CT.

Fuelcell Energy Inc

FuelCell Energy is trending following the announcement of a strategic agreement with Fit Energy to supply up to 380MW of clean, on-site power for AI data centers, with an immediate deposit for the first 30MW. While the community is debating the credibility of the partner and the structure of the deal, many bulls are focused on the validation of FCEL's utility-scale tech within the high-demand data center power sector.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending following a strategic $200 million public offering priced at $20 per share, an event that has sparked intense debate among retail investors regarding dilution versus long-term capital strength. The community is actively discussing the timing of this raise ahead of key upcoming catalysts, including IZAR-1 Phase 3 trial data, while balancing concerns over executive share sales with optimism that the strengthened balance sheet improves the company's leverage for a potential buyout.

Maase, Inc. engages in providing and operating integrated artificial intelligence (AI) digital systems. It focuses on flexible energy deployment and intelligent commercial network operation and offers closed-loop solutions from computing infrastructure, smart hardware, and full-scene services. The company was founded by Hai Feng Yu on August 6, 2018 and is headquartered in Qingdao, China.

Maase Inc. - Ordinary Shares - Class A

Highest Performances Holdings Inc. - ADR

MAAS is generating significant community interest driven by aggressive momentum, a low public float, and strategic pivots into high-growth AI infrastructure and green energy hardware. Traders are actively debating the stock's potential for further breakout volatility, balancing excitement over its technical setup against the inherent risks associated with small-cap tickers and its volatile intraday rhythm.

Hertz Global Holdings, Inc. engages in the vehicle rental business through Hertz, Dollar, and Thrifty brands. It operates through the following business segments: Americas Rental Car (RAC) and International Rental Car (RAC). The Americas RAC segment focuses on operations in the United States, Canada, Latin America, and the Caribbean. The International RAC segment includes the provision of rental and sales of vehicles and value-added services in other locations. The company was founded in 1918 and is headquartered in Estero, FL.

Hertz Global Holdings Inc. - Ordinary Shares (New)

Hertz Global Holdings Inc

Hertz is currently trending as investors weigh an unexpected drop in guidance against potential long-term growth opportunities from its new autonomous vehicle fleet management partnership with Uber. The community is actively debating the company's turnaround viability, with many closely watching how these strategic shifts compare to historical rental car market volatility.

Absci Corp. is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. It partners with pharma and biotech innovators to create the next generation of protein-based drugs. The company was founded by Sean McClain in 2011 and is headquartered in Vancouver, WA.

Absci Corp

Absci Corp is trending as investors react to positive interim phase 1 data for its hair loss antibody, ABS-201, alongside a new $100 million equity offering that includes participation from Eli Lilly. The community is heavily debating the stock's long-term potential in AI-driven drug discovery versus concerns over dilution and short-term price volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Korro Bio, Inc. (KRRO) Soars 17.6%: Is Further Upside Left in the Stock?

Korro Bio, Inc. (KRRO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Is Amarin (AMRN) Outperforming Other Medical Stocks This Year?

Here is how Amarin (AMRN) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.

AMNEAL PHARMACEUTICALS, INC. (AMRX) Hits Fresh High: Is There Still Room to Run?

Amneal (AMRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Dispensary of Hope Launches "Hope Alliance" Campaign with Support from Amneal Pharmaceuticals

Dispensary of Hope Launches "Hope Alliance" Campaign with Support from Amneal Pharmaceuticals Dispensary of Hope Launches "Hope Alliance" Campaign with Support from Amneal Pharmaceuticals PR Newswire NASHVILLE, Tenn., June 10, 2026 Amneal's Commitment Helps Support a Reliable Supply of Essential...

Amneal and Pfizer GLP-1 Deal: New Growth Lever?

AMRX is expanding into GLP-1 manufacturing and biosimilars, using partnerships and acquisitions to strengthen its higher-value product strategy.

Is Amneal a Buy Before Rytary Generic Erosion?

AMRX faces Rytary generic pressure in 2026, but growth in generics, injectables, biosimilars, and higher profitability targets could support its outlook.

What's Driving Amneal's 2026 Growth Outlook?

AMRX's 2026 outlook is driven by higher profit expectations, a steady launch cadence, and growth from complex generics, injectables, and specialty brands.

Here's Why Amneal Pharmaceuticals (AMRX) is a Strong Growth Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Amneal Stock Up on FDA Nod for Romidepsin Injection Solution

AMRX gains after FDA approval of ready-to-use romidepsin injection, with 180-day exclusivity and a potential boost to its injectables portfolio.

Is Amneal Pharmaceuticals (AMRX) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Amneal Pharmaceuticals, Inc. is a medicine company, which engages in the provision of pharmaceuticals. Its product portfolio includes generics, specialty, biosciences, and product catalog. It operates through the following segments: Generics, Specialty, and AvKARE. The Generics segment relates to oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, and transdermal patches and topicals. The Specialty segment refers to the development, promotion, sale, and distribution of proprietary branded pharmaceutical products. The AvKARE segment provides pharmaceuticals, medical, and surgical products and services to governmental agencies. The company was founded by Chirag K. Patel and Chintu Patel in 2002 and is headquartered in Bridgewater, NJ.

Amneal Pharmaceuticals Inc - Ordinary Shares - Class A

Amneal Pharma Stock Rises On FDA Approval For Generic Version Of AbbVie’s Eyedrops

Equity

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$16.66
Prev Close	$16.11
Open	$16.00
Dividend Yield	0.00%
50-Day Moving Average	$13.51
Beta	1.02
Avg. Volume	1.56M
PE Ratio	44.66

52-Week High	$16.73
52-Week Low	$7.67
Market Capitalization	$5.31B
EPS (Annual)	$0.2218
Price to Book	-117.03
Revenue Per Employee	$355,148.23

Feed

News

Sentiment

Earnings

Fundamentals

Info

AMRXAmneal Pharmaceuticals Inc - Ordinary Shares - Class A

Latest AMRX News